The Onglyza heart failure lawsuit refers to multidistrict litigation brought against Bristol-Myers Squibb and AstraZeneca by patients who alleged the diabetes medication caused or contributed to heart failure. The litigation ultimately ended unfavorably for plaintiffs in 2024 when federal courts excluded key expert testimony and granted summary judgment to the drug manufacturers. No settlements or jury verdicts were ever reached, and most law firms are no longer accepting new Onglyza cases. The lawsuits stemmed from findings in the SAVOR-TIMI 53 clinical trial, which showed that patients taking Onglyza (saxagliptin) had a 27 percent increased relative risk of hospitalization for heart failure compared to those on placebo.
This prompted the FDA to require new warning labels in April 2016. At its peak, the MDL consolidated approximately 239 to 300 lawsuits in the Eastern District of Kentucky. However, the Sixth Circuit Court of Appeals’ decision to exclude the plaintiffs’ sole expert witness effectively ended any chance of recovery for those who filed claims. This article examines the clinical evidence that sparked the litigation, how the lawsuits progressed through the court system, why plaintiffs ultimately lost, and what this outcome means for patients who experienced heart failure while taking Onglyza.
Table of Contents
- What Caused the Onglyza Heart Failure Lawsuits?
- FDA Response and Label Changes
- How the Multidistrict Litigation Took Shape
- Current Status: MDL Closed With No Recovery
- Lessons for Patients Taking Diabetes Medications
- Looking Forward: Pharmaceutical Litigation Standards
- Conclusion
What Caused the Onglyza Heart Failure Lawsuits?
Onglyza, a DPP-4 inhibitor approved by the FDA in July 2009, was marketed as a treatment for type 2 diabetes. Like many diabetes medications, it underwent post-approval safety studies to monitor cardiovascular outcomes. The SAVOR-TIMI 53 trial enrolled 16,492 patients with type 2 diabetes in a randomized, double-blind study with a mean follow-up period of 2.1 years. The results raised serious concerns.
Among patients taking saxagliptin, 289 (3.5 percent) were hospitalized for heart failure compared to 228 (2.8 percent) on placebo. This translated to a hazard ratio of 1.27, meaning patients on Onglyza were 27 percent more likely to be hospitalized for heart failure than those taking a placebo. While the absolute risk increase of 0.7 percent over two years might seem modest, it represented a statistically significant finding with a P-value of 0.007. For comparison, consider a patient with pre-existing cardiovascular risk factors who was prescribed Onglyza to manage their diabetes. If that patient later developed heart failure requiring hospitalization, the SAVOR-TIMI 53 data suggested the medication itself may have contributed to that outcome rather than being merely coincidental to their underlying health conditions.
FDA Response and Label Changes
The FDA took the clinical trial findings seriously. On April 5, 2016, the agency issued a drug safety communication requiring new warning labels for both Onglyza and Kombiglyze XR (a combination product containing saxagliptin). The updated labels specifically warned about the increased risk of heart failure hospitalization. The FDA went further than simply requiring label changes.
The agency advised healthcare professionals to “consider discontinuing medications containing saxagliptin and alogliptin in patients who develop heart failure.” This guidance acknowledged that for some patients, the risks of continuing the medication outweighed its benefits for blood sugar control. However, the FDA stopped short of issuing a recall or contraindication. This distinction matters legally because plaintiffs in drug liability cases often rely on FDA actions to establish that a drug is unreasonably dangerous. A warning requirement, while significant, does not carry the same weight as a recall. Patients with mild diabetes who had multiple alternative treatment options faced a different risk-benefit calculation than those with severe, difficult-to-control diabetes for whom Onglyza was particularly effective.
How the Multidistrict Litigation Took Shape
In February 2018, the U.S. Judicial Panel on Multidistrict Litigation created MDL No. 2809, consolidating Onglyza lawsuits in the Eastern District of Kentucky under Judge Karen Caldwell. A second MDL was later formed in California under Judge Anna-Christine Massullo. Consolidation allowed for coordinated pretrial proceedings, including discovery and motions practice, across hundreds of individual cases. At its peak, the Kentucky MDL contained between 239 and 300 individual lawsuits. Each plaintiff alleged that they had taken Onglyza as prescribed and subsequently developed heart failure, claiming the manufacturers failed to adequately warn about known risks and that the drug was defectively designed. For example, a typical plaintiff might have been a 60-year-old patient with type 2 diabetes who began taking Onglyza in 2012, developed congestive heart failure in 2015, and filed suit after learning about the SAVOR-TIMI 53 findings and the 2016 FDA warning. These cases required establishing both general causation (that Onglyza can cause heart failure) and specific causation (that Onglyza caused this particular plaintiff’s heart failure).
## Why Plaintiffs Lost: The Expert Witness Problem The litigation effectively ended in February 2024 when the U.S. Sixth Circuit Court of Appeals excluded the plaintiffs’ sole expert witness on causation. In pharmaceutical litigation, expert testimony is essential to establish that a drug caused the alleged injury. Without admissible expert testimony, plaintiffs cannot meet their burden of proof. The appellate court found that the expert’s methodology was insufficient because it relied too heavily on a single study and applied scientific criteria inconsistently. Under the Daubert standard, federal courts act as gatekeepers to ensure expert testimony is based on reliable scientific methodology. The court concluded that the plaintiffs’ expert failed to meet this threshold. This ruling illustrates a critical limitation in pharmaceutical litigation. Even when clinical data suggests an association between a drug and an adverse outcome, translating that population-level data into proof of individual causation presents significant scientific and legal challenges. The SAVOR-TIMI 53 trial showed a statistical association, but plaintiffs needed expert testimony to bridge the gap between “increased risk in a large population” and “this drug caused this specific patient’s heart failure.”.
Current Status: MDL Closed With No Recovery
Following the Sixth Circuit’s ruling, summary judgment was granted in favor of Bristol-Myers Squibb and AstraZeneca in both the Kentucky and California MDLs. The litigation is now closed. No public settlements were announced, and no jury verdicts were reached. For patients who filed lawsuits or were considering doing so, this outcome means there will be no financial recovery through the litigation process.
Most plaintiffs’ law firms have stopped accepting new Onglyza cases, recognizing that the evidentiary path forward has been effectively blocked. This result contrasts sharply with other pharmaceutical MDLs that have resulted in multi-billion dollar settlements. The difference often comes down to the strength of the scientific evidence and whether plaintiffs can present admissible expert testimony. In the Onglyza litigation, despite clinical trial data showing increased risk, plaintiffs could not clear the evidentiary hurdles required in federal court.
Lessons for Patients Taking Diabetes Medications
The Onglyza litigation outcome does not mean the drug is safe for all patients or that the heart failure concerns were unfounded. The SAVOR-TIMI 53 data remains valid scientific evidence of increased risk. What it means is that the legal system required a higher standard of proof than plaintiffs could provide.
Patients currently taking Onglyza or Kombiglyze XR should discuss their cardiovascular risk factors with their physicians. Those with pre-existing heart conditions, a history of heart failure, or multiple cardiovascular risk factors may want to explore alternative diabetes medications. Several other drug classes, including SGLT2 inhibitors, have actually demonstrated cardiovascular protective effects in clinical trials.
Looking Forward: Pharmaceutical Litigation Standards
The Onglyza case may influence how future pharmaceutical cases are litigated and evaluated. Plaintiffs’ attorneys will likely scrutinize their expert witness strategies more carefully, particularly when relying on single studies to establish causation.
Defense attorneys, meanwhile, have a new precedent for challenging expert methodology in drug-injury cases. For patients harmed by medications, the case underscores the importance of early legal consultation and the unpredictable nature of complex pharmaceutical litigation. Statistical association, even when published in major medical journals and acknowledged by the FDA, does not guarantee success in court.
Conclusion
The Onglyza heart failure lawsuit represents a significant pharmaceutical litigation that ended without any recovery for plaintiffs. Despite clinical evidence showing a 27 percent increased risk of heart failure hospitalization and an FDA warning requiring label changes, the consolidated lawsuits failed when courts excluded key expert testimony. The approximately 239 to 300 cases that were part of the MDL were dismissed following summary judgment in favor of the manufacturers.
Patients who took Onglyza and developed heart failure have limited legal options at this point, as most firms have stopped accepting new cases. Those still taking the medication should consult with their healthcare providers about their individual risk factors and potential alternatives. The litigation’s outcome serves as a reminder that pharmaceutical cases depend heavily on the ability to present reliable expert testimony that meets rigorous federal court standards.